202 related articles for article (PubMed ID: 34663644)
1. Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study.
Delva A; Michiels L; Koole M; Van Laere K; Vandenberghe W
Neurology; 2022 Jan; 98(1):e83-e94. PubMed ID: 34663644
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
[TBL] [Abstract][Full Text] [Related]
3. Healthy brain aging assessed with [
Andersen KB; Hansen AK; Knudsen K; Schacht AC; Damholdt MF; Brooks DJ; Borghammer P
Nucl Med Biol; 2022; 112-113():52-58. PubMed ID: 35820300
[TBL] [Abstract][Full Text] [Related]
4. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
[TBL] [Abstract][Full Text] [Related]
5. Synaptic density in healthy human aging is not influenced by age or sex: a
Michiels L; Delva A; van Aalst J; Ceccarini J; Vandenberghe W; Vandenbulcke M; Koole M; Lemmens R; Laere KV
Neuroimage; 2021 May; 232():117877. PubMed ID: 33639258
[TBL] [Abstract][Full Text] [Related]
6. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
[TBL] [Abstract][Full Text] [Related]
7. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [
Chen MK; Mecca AP; Naganawa M; Gallezot JD; Toyonaga T; Mondal J; Finnema SJ; Lin SF; O'Dell RS; McDonald JW; Michalak HR; Vander Wyk B; Nabulsi NB; Huang Y; Arnsten AF; van Dyck CH; Carson RE
J Cereb Blood Flow Metab; 2021 Sep; 41(9):2395-2409. PubMed ID: 33757318
[TBL] [Abstract][Full Text] [Related]
9. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
[TBL] [Abstract][Full Text] [Related]
10. Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters.
López Mora DA; Sampedro F; Camacho V; Fernández A; Fuentes F; Duch J; Pérez-Perez J; Martínez-Horta S; Marín-Lahoz J; Domènech A; Flotats A; Estorch M; Kulisevsky J; Carrió I
Clin Nucl Med; 2019 Jan; 44(1):e1-e5. PubMed ID: 30325816
[TBL] [Abstract][Full Text] [Related]
11. Generation of synthetic PET images of synaptic density and amyloid from
Wang R; Liu H; Toyonaga T; Shi L; Wu J; Onofrey JA; Tsai YJ; Naganawa M; Ma T; Liu Y; Chen MK; Mecca AP; O'Dell RS; van Dyck CH; Carson RE; Liu C
Med Phys; 2021 Sep; 48(9):5115-5129. PubMed ID: 34224153
[TBL] [Abstract][Full Text] [Related]
12. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
Delva A; Van Weehaeghe D; Koole M; Van Laere K; Vandenberghe W
Mov Disord; 2020 Nov; 35(11):1977-1986. PubMed ID: 32767618
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
Delva A; Van Laere K; Vandenberghe W
Mov Disord; 2022 Sep; 37(9):1883-1892. PubMed ID: 35819412
[TBL] [Abstract][Full Text] [Related]
14. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
[TBL] [Abstract][Full Text] [Related]
15. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
[TBL] [Abstract][Full Text] [Related]
16. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
Kumar A; Scarpa M; Nordberg A
Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Evaluation of
Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
[TBL] [Abstract][Full Text] [Related]
18. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [
Andersen KB; Hansen AK; Schacht AC; Horsager J; Gottrup H; Klit H; Danielsen EH; Poston KL; Pavese N; Brooks DJ; Borghammer P
Mov Disord; 2023 May; 38(5):796-805. PubMed ID: 36905188
[TBL] [Abstract][Full Text] [Related]
19. Cortical abnormalities of synaptic vesicle protein 2A in focal cortical dysplasia type II identified in vivo with
Tang Y; Yu J; Zhou M; Li J; Long T; Li Y; Feng L; Chen D; Yang Z; Huang Y; Hu S
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3482-3491. PubMed ID: 34978594
[TBL] [Abstract][Full Text] [Related]
20. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
